AU2004247021A1 - Compositions and methods including a recombinant human MAB that promotes CNS remyelination - Google Patents

Compositions and methods including a recombinant human MAB that promotes CNS remyelination Download PDF

Info

Publication number
AU2004247021A1
AU2004247021A1 AU2004247021A AU2004247021A AU2004247021A1 AU 2004247021 A1 AU2004247021 A1 AU 2004247021A1 AU 2004247021 A AU2004247021 A AU 2004247021A AU 2004247021 A AU2004247021 A AU 2004247021A AU 2004247021 A1 AU2004247021 A1 AU 2004247021A1
Authority
AU
Australia
Prior art keywords
antibody
antibodies
human
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004247021A
Other languages
English (en)
Inventor
Allan J. Bieber
Eric Chojnicki
Elliot A. Gruskin
Moses Rodriguez
Arthur E. Warrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Acorda Therapeutics Inc
Original Assignee
Mayo Foundation for Medical Education and Research
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Acorda Therapeutics Inc filed Critical Mayo Foundation for Medical Education and Research
Publication of AU2004247021A1 publication Critical patent/AU2004247021A1/en
Priority to AU2010202111A priority Critical patent/AU2010202111B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004247021A 2003-05-16 2004-05-17 Compositions and methods including a recombinant human MAB that promotes CNS remyelination Abandoned AU2004247021A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010202111A AU2010202111B2 (en) 2003-05-16 2010-05-25 Compositions and methods including a recombinant human MAB that promotes CNS remyelination

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47123503P 2003-05-16 2003-05-16
US60/471,235 2003-05-16
PCT/US2004/015436 WO2004110355A2 (en) 2003-05-16 2004-05-17 Compositions and methods including a recombinant human mab that promotes cns remyelination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010202111A Division AU2010202111B2 (en) 2003-05-16 2010-05-25 Compositions and methods including a recombinant human MAB that promotes CNS remyelination

Publications (1)

Publication Number Publication Date
AU2004247021A1 true AU2004247021A1 (en) 2004-12-23

Family

ID=33551425

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004247021A Abandoned AU2004247021A1 (en) 2003-05-16 2004-05-17 Compositions and methods including a recombinant human MAB that promotes CNS remyelination
AU2010202111A Ceased AU2010202111B2 (en) 2003-05-16 2010-05-25 Compositions and methods including a recombinant human MAB that promotes CNS remyelination

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010202111A Ceased AU2010202111B2 (en) 2003-05-16 2010-05-25 Compositions and methods including a recombinant human MAB that promotes CNS remyelination

Country Status (8)

Country Link
US (5) US8460665B2 (enExample)
EP (1) EP1648427B1 (enExample)
JP (1) JP2007505157A (enExample)
AU (2) AU2004247021A1 (enExample)
CA (2) CA2525917C (enExample)
ES (1) ES2451993T3 (enExample)
PL (1) PL1648427T3 (enExample)
WO (1) WO2004110355A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
WO2009104100A2 (en) * 2008-02-19 2009-08-27 Patrys Limited Antibody combinations, and methods of making and using same
WO2012054077A2 (en) 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012149024A2 (en) 2011-04-28 2012-11-01 Mayo Foundation For Medical Education And Research Dna aptamers for promoting remyelination
BR112014025898A2 (pt) 2012-04-17 2017-11-07 Mayo Found Medical Education & Res anticorpos humanos e sequências de ligação específica, para uso em acidente vascular cerebral e isquemia ou condições isquêmicas
WO2016073963A1 (en) 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
US11999778B2 (en) 2016-05-13 2024-06-04 The Board Of Regents Of The University Of Texas System VH4 antibodies and compositions comprising the same
EP3401682A1 (en) * 2017-05-09 2018-11-14 Université de Nantes Diagnosis, prevention and treatment of demyelinating disorders of the central nervous system
WO2020118218A1 (en) 2018-12-06 2020-06-11 Mayo Foundation For Medical Education And Research Short dna aptamers and methods for promoting remyelination

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5591629A (en) * 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP2287190B1 (en) * 2000-05-10 2014-12-17 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
JP2008127346A (ja) 2006-11-22 2008-06-05 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症および神経疾患を治療および予防するための医薬

Also Published As

Publication number Publication date
CA2967294A1 (en) 2004-12-23
US20200247883A1 (en) 2020-08-06
EP1648427B1 (en) 2013-12-18
US8460665B2 (en) 2013-06-11
CA2525917A1 (en) 2004-12-23
PL1648427T3 (pl) 2014-05-30
CA2525917C (en) 2017-07-04
AU2010202111B2 (en) 2012-11-15
EP1648427A4 (en) 2007-04-11
ES2451993T3 (es) 2014-03-28
US20070086999A1 (en) 2007-04-19
US9751943B2 (en) 2017-09-05
CA2967294C (en) 2020-04-28
AU2010202111A1 (en) 2010-06-17
WO2004110355A3 (en) 2006-05-18
US20130309240A1 (en) 2013-11-21
US20180179277A1 (en) 2018-06-28
WO2004110355A2 (en) 2004-12-23
EP1648427A2 (en) 2006-04-26
JP2007505157A (ja) 2007-03-08
US20150299316A1 (en) 2015-10-22
US8968735B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
US20200247883A1 (en) Compositions and methods including a recombinant human mab that promotes cns remyelination
US10351620B2 (en) Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
AU2000261978B2 (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
AU2000261978A1 (en) Human IgM antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP3013362A1 (en) Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
JPH08506325A (ja) サイトメガロウイルスに対するヒトモノクローナル抗体
HK1154605A (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
HK1154604B (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
HK1154605B (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted